Wendy Johnson

Wendy Johnson is a seasoned professional in the life sciences industry, currently serving as the Interim Chief Business Officer at Riva Therapeutics since September 2022. Wendy has been the Managing Director at Gemini Advisors since March 2014, providing development and strategic services to life science companies. Prior experience includes serving as Chief Business Officer at Reneo Pharmaceuticals, where Wendy oversaw the development of Mavodelpar for primary mitochondrial myopathy until October 2024, and held board positions at Exagen Inc. and MorphoSys AG. Educational accomplishments include an MBA from Loyola University Maryland and a B.S. in Microbiology from the University of Maryland.